Page 2 - Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages […]

Guggenheim lowered shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) from a buy rating to a neutral rating in a report published on Friday, MarketBeat reports. Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) shares shot up 5.3% during mid-day trading on Thursday . The company traded as high as $3.40 and last traded at $3.37. 776,875 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 2,204,204 shares. The stock had previously closed at […]

Citigroup started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock. ALLO has been the topic of a number of other research reports. JPMorgan Chase & Co. cut their […]

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last posted its earnings results on Wednesday, August 2nd. The company reported ($0.53) […]